Literature DB >> 24273488

Promoting Effects of Heparin on ex vivo Expansion of Megakaryocytopoiesis from Human Cord Blood CD34+ Cells.

Anne-Marie Maurer1, Altay Gezer.   

Abstract

INTRODUCTION: Transfusion of ex vivo expanded megakaryocytes (MKs) has been proposed to sustain platelet recovery after cord blood (CB) hematopoietic stem cell transplantation. In this study, we investigated the effects of heparin on ex vivo colony forming unit-megakaryocytes (CFU-MKs) and MKs expansion from CB CD34+ cells.
METHODS: CB CD34+ cells were stimulated by a combination of thrombopoietin (TPO), stem cell factor (SCF), Flt3-Ligand (FL), IL-6, and IL-11 supplemented with autologous serum and heparin during 14 days. Expanded cells were analyzed by flow cytometry and cultured in a CFU-MK assay.
RESULTS: Compared to control cultures, the 5-factor combination with heparin induced significantly (p ≤ 0.05) higher numbers of: CFU-MKs and CD41+ cells on days 7 and 14; CD41+ cells displaying hyperploidy levels (≥8N) on day 14; platelets on day 14. The culture-derived platelets were activated upon collagen stimulation.
CONCLUSION: Heparin can significantly enhance the stimulating effects of a combination of TPO, SCF, FL, IL-6, and IL-11 supplemented with autologous serum on CFU-MK, MK, and platelet production from CB CD34+ cells. This expansion system could represent a promising method to generate CFU-MKs and MKs cells for transfusion to sustain platelet reconstitution following CB transplantation.

Entities:  

Keywords:  CD34+ cells; Cord blood; Expansion; Glycosaminoglycan; Megakaryocytopoiesis

Year:  2013        PMID: 24273488      PMCID: PMC3822282          DOI: 10.1159/000355519

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  34 in total

1.  Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System.

Authors:  Jennifer Jaroscak; Kristin Goltry; Alan Smith; Barbara Waters-Pick; Paul L Martin; Timothy A Driscoll; Richard Howrey; Nelson Chao; Judy Douville; Sue Burhop; Pingfu Fu; Joanne Kurtzberg
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

2.  Thrombopoietin requires additional megakaryocyte-active cytokines for optimal ex vivo expansion of megakaryocyte precursor cells.

Authors:  J L Williams; G G Pipia; N S Datta; M W Long
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

Review 3.  The extracellular matrix of the hematopoietic microenvironment.

Authors:  G Klein
Journal:  Experientia       Date:  1995-09-29

4.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

Authors:  F J de Sauvage; P E Hass; S D Spencer; B E Malloy; A L Gurney; S A Spencer; W C Darbonne; W J Henzel; S C Wong; W J Kuang
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

5.  Transplantation of ex vivo expanded cord blood.

Authors:  Elizabeth J Shpall; Ralph Quinones; Roger Giller; Chan Zeng; Anna E Baron; Roy B Jones; Scott I Bearman; Yago Nieto; Brian Freed; Nancy Madinger; Christopher J Hogan; Vicki Slat-Vasquez; Peggy Russell; Betsy Blunk; Deborah Schissel; Elaine Hild; Janet Malcolm; William Ward; Ian K McNiece
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

6.  Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial.

Authors:  M de Lima; J McMannis; A Gee; K Komanduri; D Couriel; B S Andersson; C Hosing; I Khouri; R Jones; R Champlin; S Karandish; T Sadeghi; T Peled; F Grynspan; Y Daniely; A Nagler; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2008-01-21       Impact factor: 5.483

7.  Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines.

Authors:  E Bruno; S D Luikart; M W Long; R Hoffman
Journal:  Exp Hematol       Date:  1995-10       Impact factor: 3.084

8.  Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy.

Authors:  A Kessinger; J O Armitage; J D Landmark; D M Smith; D D Weisenburger
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

Review 9.  Umbilical cord blood transplantation: the first 20 years.

Authors:  John E Wagner; Eliane Gluckman
Journal:  Semin Hematol       Date:  2010-01       Impact factor: 3.851

10.  Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: an alternative approach.

Authors:  S F Williams; J D Bitran; J M Richards; P J DeChristopher; E Barker; J Conant; H M Golomb; A R Orlina
Journal:  Bone Marrow Transplant       Date:  1990-02       Impact factor: 5.483

View more
  4 in total

1.  Hematopoietic Growth Factors in Transfusion Medicine and Cellular Therapy - Part II.

Authors:  Peter Schlenke; Andreas Humpe
Journal:  Transfus Med Hemother       Date:  2013-10       Impact factor: 3.747

2.  Comparative analysis of autologous blood transfusion and allogeneic blood transfusion in surgical patients.

Authors:  Miao-Yun Long; Zhong-Han Liu; Jian-Guang Zhu
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Hyaluronan based hydrogels provide an improved model to study megakaryocyte-matrix interactions.

Authors:  Manuela Currao; Alessandro Malara; Christian A Di Buduo; Vittorio Abbonante; Lorenzo Tozzi; Alessandra Balduini
Journal:  Exp Cell Res       Date:  2015-05-29       Impact factor: 3.905

4.  In vitro and in vivo evaluation of cord blood hematopoietic stem and progenitor cells amplified with glycosaminoglycan mimetic.

Authors:  Lionel Faivre; Véronique Parietti; Fernando Siñeriz; Sandrine Chantepie; Marie Gilbert-Sirieix; Patricia Albanese; Jérôme Larghero; Valérie Vanneaux
Journal:  Stem Cell Res Ther       Date:  2016-01-07       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.